



PHARMACY AND POISONS BOARD

NEWSLETTER

web.pharmacyboardkenya.org



**Pharmacy and Poisons Board
Enters a Strategic Alliance with
US FDA to Advance
Regulatory Standards**



REPUBLIC OF KENYA

**MINISTRY OF HEALTH
Pharmacy and Poisons Board**

PUBLIC ALERT

**WARNING REGARDING SUSPECTED FALSIFIED THEMRA EPIMEDYUMLU
MACUN (“ASALI YA WAZEE”) MANUFACTURED BY VEYSI TOPUZ**

The Pharmacy and Poisons Board (PPB) wishes to alert the public about a suspected falsified product, THEMRA Epimedyumlu Macun, manufactured by Veyisi Topuz that is believed to be in circulation within the Kenyan market. The product, commonly referred to as **“Asali ya wazee”**, is promoted for its alleged sexual enhancement properties and is claimed to be herbal and 100% natural.

Consequently, the PPB has conducted thorough tests on the honey-based product, and detected significant adulteration of the product with high levels of a conventional active pharmaceutical ingredient, known as Sildenafil, which is prescribed for management of erectile dysfunction and pulmonary arterial hypertension. The PPB informs the public that Sildenafil is classified as a Prescription-Only Medicine and its excessive consumption poses serious safety and health hazards.

In view of the above, the PPB strongly cautions the public against use or involvement in the trade, distribution, wholesale, retail, issuance or dispensing of this product. Any person found dealing with or distributing these products will be subjected to legal action.

Further, the PPB advises the public against use of health products that have not obtained approval from the PPB.


We encourage both the general public and healthcare providers to promptly report any suspected substandard and falsified medical products to the PPB using the following channels:

- Website: <https://pv.pharmacyboardkenya.org/users/mpublic>
- Mobile Application: mPvERS both android & iOS
- USSD code at *271#,
- Email: pv@pharmacyboardkenya.org
- Telephone: +254 795 743 049


Dr. F. M. Siyoi

CHIEF EXECUTIVE OFFICER

21st November 2023



Editorial Board

Editorial Advisor

Dr. Anthony Toroitich

Editor

Judy Sirima

Contributors

Judy Sirima

Naomi Naanyu

About The Newsletter

The PPB Newsletter is a publication of the Public Relations Department. It is designed to act as a tool of communication, documenting and disseminating important news and information to staff and stakeholders of the Board

Contacts

Department of Public Relations,
Pharmacy and Poisons Board,
Lenana Road

P.O. Box 27663-00506 Nairobi.

Tel: +254-709-770-100

Email: pr@ppb.go.ke
info@ppb.go.ke

Web: web.pharmacyboardkenya.org

Design and Layout

Commwide Concepts

Email: commwideconcepts@gmail.com

Editor's Note

In Our 26th Edition

Dear Readers,

Welcome to the 26th edition of Pharmacy and Poisons Board Newsletter. In this issue, we are pleased to bring comprehensive updates on the latest regulations, advancements and insights shaping the pharmaceutical landscape.

From innovative and evolving regulatory frameworks, we aim provide you with timely and relevant information to support informed decision-making and best practices in pharmacy practice.

As always we encourage our readers to with the content and contribute to the ongoing dialogue medication safety and public health.

Thank you for your continued support, and we hope you find this edition both informative and valuable.

Judy

UPCOMING EVENTS

- WHO Observed Audits
- PSK Annual Scientific Conference
- KPA Annul Scientific Conference



PHARMACY AND POISONS BOARD

pr@ppb.go.ke
info@ppb.go.ke



Pharmacy and Poisons Board



@ppbkenya

CONTENTS

- 5 Pharmacy and Poisons Board Inks Deal with Anti-counterfeit Authority.**
- 5 Pharmacy and Poisons Board Attains Milestone as MDSAP Affiliate Member, Enhancing Medical Devices Regulatory Standards in Kenya.**
- 6 Pharmacy and Poisons Board Enters a Strategic Alliance with US FDA to Advance Regulatory Standards.**
- 7 Pharmacy and Poisons Board Advances Towards Regulatory Excellence.**
- 8 Pharmacy and Poisons Board Inaugurates the Technical Expert and Advisory Committee.**
- 8 Pharmacy and Poisons Board Conducts Workshop to Develop National Pharmacovigilance Risk Communication.**
- 9 Pharmacy and Poisons Board Hosts Workshop to Elevate Local Health Products and Technologies.**
- 10 Pharmacy and Poisons Board Engages Top Management from Local Pharmaceutical Manufacturers.**
- 10 Pharmacy and Poisons Board Facilitates Collaboration for Effective Clinical Research.**
- 11 Pharmacy and Poisons Board Crackdown: 129 Arrested in Illegal pharmaceutical Outlets Operation.**
- 12 Pharmacy and Poisons Board Cracks Down: 24 Arrested in Operation Targeting Illegal Pharmaceutical Outlets.**
- 12 Director from Bill and Melinda Gates Foundation Visits Pharmacy and Poisons Board to Strengthen Regulatory Systems.**
- 13 Pharmacy and Poisons Board Strengthens Pharmaceutical Compliance in Western Region through Key Engagement.**
- 13 Enquiries and Disciplinary Committee (EDC) of the Pharmacy and Poisons Board Holds Deliberations with Kenya Pharmaceutical Association and Pharmaceutical Society of Kenya.**
- 14 Pharmacy and Poisons Board Participates in the Government Performance and Delivery Roadshow.**
- 15 Pharmacy and Poisons Board CEO Engages with PMI Kenya Team.**
- 15 Pharmacy and Poisons Board CEO Hosts MSH Vice President Dr. Day Adetosoye.**
- 16 Pharmacy and Poisons Board CEO Hosts U.S. Pharmacopeia Vice President and PQM+ Director for Enhanced Collaborative Initiatives.**
- 16 Pharmacy and Poisons Board Hosts Algerian Trade Mission.**
- 17 Pharmacy and Poisons Board Chairman and CEO Host Biovax Institute Top Leadership.**
- 17 Pharmacy and Poisons Board Shares Clinical Trials Insights with Walter Reed Army Institute of Research.**
- 18 Pharmacy and Poisons Board Conducts Workshop to Enhance Quality of HPTs.**
- 19 Pharmacy and Poisons Board Engages KAPI and MEDAK Stakeholders.**

Pharmacy and Poisons Board Inks Deal with Anti-counterfeit Authority



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi and his Anti Counterfeit Authority counterpart Dr. Robi Njoroge display the signed MOU.

Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi and his Anti Counterfeit Authority counterpart Dr. Robi Njoroge sign the Memorandum of Understanding.

In a significant development, the Pharmacy and Poisons Board (PPB) and the Anti-Counterfeit Authority (ACA Kenya) of Kenya collaboratively signed a Memorandum of Understanding on January 16, 2024, to combat counterfeit medicines.

The MOU, signed by PPB Chief Executive Officer Dr. Fred Siyoi and his ACA Kenya counterpart

Dr. Robi Njoroge Mbugua, aims to strengthen the regulation and enforcement of health product and technology owners' rights, focusing on preventing the circulation of counterfeit health products within Kenya.

The two CEOs expressed optimism about the MOU enhancing Intellectual Property rights enforcement in the pharmaceutical

sector. The MOU outlines a comprehensive framework covering various aspects, including information sharing, joint investigations, capacity building, research, regulatory harmonization, and regular communication between the agencies.

This initiative is crucial in addressing challenges posed by technological advancement, porous borders, and limited resources within the agencies, signifying a proactive approach to safeguarding the integrity of health products and technologies in Kenya.

Pharmacy and Poisons Board Attains Milestone as MDSAP Affiliate Member, Enhancing Medical Devices Regulatory Standards in Kenya

The Pharmacy and Poisons Board (PPB) has achieved a significant milestone by obtaining official recognition as an MDSAP Affiliate Member for the Medical Devices Single Audit Program (MDSAP).

This acknowledgment was made during the 25th session of the International Medical Devices Regulators Forum (IMDRF) in Washington DC, which took place from March 11th to 14th, 2024.

Dr. Paulyne Wairimu, Chair of the

African Medical Devices Forum and PPB's Medical Devices Lead, along with Dr. Kariuki Gachoki, Deputy Director of the Department of Product Evaluation and Registration, represented PPB at the event, hosted by the US-FDA as Secretariat.

By joining a network of regulators including the U.S. Food and Drug Administration, UK-Medicines & Healthcare Products Regulatory Agency (MHRA), Health Canada,



Pharmacy and Poisons Board Head of Medical Devices makes her remarks during the meeting.

Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Australia's Therapeutic Goods Administration (TGA), and Brazil's The Brazilian Health Regulatory Agency (ANVISA), PPB is now empowered to conduct quality audits for medical devices and diagnostics.

This initiative aims to enhance regulatory standards in Kenya, aligning them with those of IMDRF member economies. PPB's leadership in Africa is underscored by its commitment to implementing a robust regulatory system for medical devices, further solidifying its position as a key player in advancing healthcare standards across the continent



Dr. Paulyne Wairimu among other panellists.



Pharmacy and Poisons Board Enters a Strategic Alliance with US FDA to Advance Regulatory Standards



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi and the US Food and Drug Administration Associate commissioner, Global Policy and Strategy Mr. Mark Abdo sign the Confidentiality Commitment

In a substantial step towards regulatory advancement, the Pharmacy and Poisons Board (PPB) has formalized a strategic partnership with the US Food and Drug Administration (US FDA) by signing a Confidentiality Commitment.

This important agreement, sealed

on March 15th, 2024, in Washington D.C., comes after a week of significant progress for PPB in the regulation of Medical Devices and Diagnostics.

Dr. Fred Siyoi, Chief Executive Officer of PPB, and Mr. Mark Abdo, Associate Commissioner for Global Policy and Strategy at the US FDA,

affirmed their commitment to regulatory excellence through this collaborative framework.

This engagement underscores PPB's proactive approach to enhancing regulatory standards and fostering international cooperation. The Confidentiality Commitment signifies a significant step towards establishing a collaborative framework between PPB and the US FDA, facilitating the exchange of critical information and promoting regulatory harmonization in the field of medical devices and diagnostics.



Pharmacy and Poisons Board Advances Towards Regulatory Excellence



Dr. Kariuki Gachoki, Deputy Director, Product Evaluation and Registration, makes his remarks during the meeting.

authorities worldwide. IMDRF includes regulatory bodies from Australia, Brazil, Canada, China, the European Union, Japan, Singapore, South Korea, the United Kingdom, and the United States.

On March 14, 2024, the Pharmacy and Poisons Board (PPB) took a significant step towards global collaboration and regulatory excellence. Under the leadership of Chief Executive Officer, Dr. F.M. Siyoi, the team convened in Washington DC to submit an application to join the International Medical Device Regulators Forum (IMDRF) as an affiliate member.

During the Management Committee Closed Session, Dr. Kariuki Gachoki, Deputy Director, Department of Product Evaluation and Registration at PPB, presented the application, reaffirming PPB’s commitment to enhancing regulatory standards and fostering global cooperation in the medical device field.

Becoming an affiliate member of IMDRF will open doors to invaluable

opportunities for learning and collaboration with regulatory



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi pose for a photo with Dr. Paulyne Wairimu and Dr. Kariuki Gachoki.

Prevention is better than Cure. When it comes to medicine safety, double check and follow instructions for a healthier tomorrow.
#Medicinesafety #HealthMatters

Pharmacy and Poisons Board Inaugurates the Technical Expert and Advisory Committee



Pharmacy and Poisons Board Chairman, Dr. Charles Githinji, Chief Executive Officer, Dr. F. M. Siyoi, board members and the Technical Experts and Advisory Committees pose for a photo.

The Pharmacy and Poisons Board (PPB) celebrated a significant milestone with the establishment of nine Technical Expert and Advisory Committees.

At an event held on March 20, 2024, attended by PPB Chairman Dr. Charles Githinji, Board Members, and Chief Executive Officer Dr. F. M. Siyoi, 81 members were appointed to serve on these committees.

Chairman Githinji highlighted the importance of adhering to the Manual for Technical & Expert

Advisory Committees, emphasizing the need for confidentiality and transparency in disclosing potential

conflicts of interest.

Upholding professional standards and regulatory practices outlined in PPB's service charter were also emphasized during the inauguration. The establishment of these committees underscores PPB's commitment to ensuring the safety, efficacy, and quality of medicines while upholding professional standards in the pharmacy sector.

With the expertise and dedication of committee members, PPB aims to advance regulatory excellence and safeguard public health for all Kenyans.



Pharmacy and Poisons Board Conducts Workshop to Develop National Pharmacovigilance Risk Communication

Risk communication is crucial in informing and educating the public about potential risks associated with the use of health products and technologies.

In light of this, the Pharmacy and Poisons Board, through its Pharmacovigilance division, led a week-long workshop to develop a National Pharmacovigilance Risk Communication and Response Plan, supported by the Medicines, Technologies,



Dr. Anthony Toroitich makes his remarks during the workshop.



A group photo of the workshop participants.



and Pharmaceutical Services (MTaPS) Program. This initiative aims to provide guidance to the PPB and stakeholders.

The National Pharmacovigilance Risk Communication and Response Plan, finalized on February 9, 2024, is a crucial element for patient safety in healthcare.

The workshop concluded with remarks from Dr. Anthony Toroitich, Product Safety Lead,

who expressed gratitude to the Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program and county representatives for their support throughout the process.

Dr. Toroitich emphasized the importance of a risk communication approach, stating it is vital for achieving WHO Global Benchmarking Tool (GBT) Level 3 and enhancing reporting and integration efforts.

Similarly, to enhance clinical trials oversight in Kenya, the Clinical Trials Division of the Pharmacy and Poisons Board, with support from the USAID/MTaPS program, hosted a workshop concurrently to develop and review regulatory instruments, particularly focusing on crafting Good Clinical Practice (GCP) inspection guidelines and offering competency training for GCP inspectors.

Pharmacy and Poisons Board Hosts Workshop to Elevate Local Health Products and Technologies



Dr. Dominic Kariuki, Deputy Director, Inspectorate and Enforcement makes his remarks during the workshop

From January 22nd to 24th, 2024, the Pharmacy and Poisons Board (PPB) organized a three-day workshop for local Health Products and Technologies (HPTs) manufacturers.



Workshop participants follow the proceedings.

The workshop aimed to disseminate insights gained from the World Health Organization Global Benchmarking Tool Audit of PPB, addressing its implications for Kenyan pharmaceutical manufacturers, common deficiencies in baseline inspections, and providing guidance for key personnel.

The focal areas included

Pharmaceutical Quality Systems, encompassing complaints, recalls, deviations, incidents, change control, and handling out-of-specifications. The initiative's goal is to enhance knowledge and elevate pharmaceutical manufacturing standards in Kenya.



A participant shares his views during the workshop.

Pharmacy and Poisons Board Engages Top Management from Local Pharmaceutical Manufacturers



Dr. Cheworei Csichey addresses the workshop participants.

On February 27, 2024, the Pharmacy and Poisons Board (PPB) convened a meeting with top management from local pharmaceutical manufacturing companies to discuss strategies for enhancing oversight of local manufacturers. The meeting highlighted the importance of implementing a rapid alert system to manage substandard and falsified medicines, as well as the application of a mandatory bioequivalence roadmap for eligible products.



Pharmacy and Poisons Board Director of Health Products and Technologies, Dr. Ahmed Mohamed, during the workshop.

Dr. Ahmed Mohamed, Director of Health Products and Technologies, representing PPB's Chief Executive Officer, Dr. F. M. Siyoi, emphasized the need for enforcing regulatory instruments and taking prompt regulatory actions in cases of noncompliance that pose risks to the quality, safety, and efficacy of health products.

He expressed gratitude to participants for their collaborative



efforts as PPB works towards achieving World Health Organization Maturity Level 3.

Pharmacy and Poisons Board Facilitates Collaboration for Effective Clinical Research



Participants pose for a photo after the workshop.

In a pivotal move towards advancing clinical research, the Pharmacy and Poisons Board's Clinical Trials Division organized a consultative forum from January 22nd to 26th, 2024.

Themed "Collaboration for Effective Clinical Research," the forum focused on enlightening stakeholders about the PPB's mandate and their crucial role in safeguarding study participants and ensuring data integrity in clinical trials.

The event gathered participants from NACOSTI, Ethics Committees, research centers, clinical trial logistics companies,

researchers, the Clinical Research Society of Kenya, and sponsor representatives. The discussions emphasized ethical

conduct, regulatory compliance, patient-centered approaches, and fostering innovation through collaboration.

Pharmacy and Poisons Board Crackdown: 129 Arrested in Illegal Pharmaceutical Outlets Operation



In a crackdown on illegal pharmaceutical outlets, the Pharmacy and Poisons Board (PPB) has apprehended 129 individuals and seized over 200 cartons of illicit medicines across Nairobi, South Rift, and Western regions. Ensuring the safety and integrity of pharmaceuticals is paramount to safeguarding public health.

The operation aimed to enforce regulatory standards, ensure public safety, and curb unlawful practices in the pharmaceutical sector. PPB, the National Drug Regulatory Authority under the Ministry of Health, conducted this operation to enforce regulatory standards and ensure public safety.

The crackdown, which started on January 29, targeted illegal pharmaceutical premises and chemists distributing unregistered medicines, posing significant risks to public health due to the lack of safety and efficacy guarantees. Kaluai Julius, Head

of Enforcement and Surveillance at PPB, emphasized the board's commitment to curbing unlawful practices in the pharmaceutical sector.

He highlighted the importance of verifying the legitimacy of pharmaceutical establishments and cautioned the public against purchasing medicines from unauthorized sources.

Healthcare facilities handling



Closure notices displayed on closed pharmaceutical outlets during the crackdowns.

pharmaceuticals are advised to apply online for the disposal of pharmaceutical waste or contact PPB regional officers for assistance.

Additionally, pharmaceutical practitioners are encouraged to review and update transportation processes for pharmaceuticals to enhance efficiency and reliability, Kaluai advised.

This successful operation reflects PPB's dedication to maintaining the integrity of the pharmaceutical industry and protecting citizens' well-being. It underscores the importance of collaborative efforts in upholding regulatory standards and safeguarding public health.



Pharmacy and Poisons Board Cracks Down: 24 Arrested in Operation Targeting Illegal Pharmaceutical Outlets



Dr. Tom Kauki, Head Central Region seizes medicines from an illegal outlet during a crackdown in Nairobi.

On March 21, 2024, the Pharmacy and Poisons Board (PPB) initiated a rigorous crackdown in Nairobi

County, resulting in the arrest of 24 individuals and the closure of 30 unlicensed chemists.

Led by PPB Inspector Dr. Tom Mwangi, the operation aimed to sanitize the pharmaceutical sector by targeting fake pharmacists and illegal pharmaceutical outlets across the country.

Dr. Mwangi emphasized the public health risks posed by these outlets, including improper storage of medicines and the unauthorized sale of narcotics and psychotropic substances.

The crackdown, which began in late January 2024, is ongoing and extends to all 47 counties nationwide. PPB's head of enforcement and surveillance, Mr. Julius Kaluai, highlighted the importance of the operation in response to a presidential directive to curb the sale and consumption of illicit drugs and alcohol.

This crackdown coincides with the PPB's implementation of guidelines to regulate pharmaceutical sales representatives, ensuring their qualifications and ethical conduct.

Director from Bill and Melinda Gates Foundation Visits Pharmacy and Poisons Board to Strengthen Regulatory Systems



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi during the meeting.

On January 27, 2024, Dr. Dan Hartman, Director of Integrated Development at the Bill and Melinda Gates Foundation (B&MGF), visited the Pharmacy and Poisons Board (PPB).

The meeting, led by PPB Chief Executive Officer Dr. F. M. Siyoi, focused on strengthening Kenya's regulatory system and achieving World Health Organization Maturity Level Three (ML3).

Dr. Siyoi affirmed the government's



Dr. Dan Hartman during a tour of the Pharmacy and Poisons Board Quality Control Laboratory.

commitment to ML3 status through regulatory enhancements, harmonization, collaboration, and operational sustainability.

Accompanied by his team,

including Dr. David Mukanga and Ms. Lorraine Danks, Dr. Hartman toured the PPB Quality Control Laboratory.

The visit showcased the Board's

testing capacity, emphasizing its dedication to maintaining regulatory excellence. This collaboration signifies a concerted effort to fortify healthcare infrastructure and enhance regulatory processes in Kenya.



Pharmacy and Poisons Board Strengthens Pharmaceutical Compliance in Western Region through Key Engagement



Mr. Solomon Kamau engages stakeholders in the workshop.



Participants follow proceedings during the workshop.

On March 25th, 2024, pharmaceutical regulatory officers from the Pharmacy and Poisons Board (PPB), led by Dr. Paddy Agoro and Solomon Kamau, conducted a strategic workshop aimed at enhancing pharmaceutical compliance in the Western region. Facilitated by the PPB regional head and the regional police commander,

the workshop brought together senior police officers, including all 13 sub-county police commanders, sub-county DCI commanders, and their deputies.

The workshop's primary objective was to familiarize law enforcement officials with PPB's mandate, the various offenses outlined in the Pharmacy and Poisons Act, and

their crucial role in enforcing regulatory directives.

Participants expressed gratitude for the opportunity and pledged to collaborate closely with PPB in the ongoing endeavor to eradicate pharmaceutical malpractice and safeguard public health in the Western region.

Enquiries and Disciplinary Committee (EDC) of the Pharmacy and Poisons Board Holds Deliberations with Kenya Pharmaceutical Association and Pharmaceutical Society of Kenya



Pharmacy and Poisons Board EDC, KPA & PSK officials pose for a photo after the meeting

On January 31, 2024, the Enquiries and Disciplinary Committee (EDC)

of the Pharmacy and Poisons Board engaged in extensive deliberations

with officials from the Kenya Pharmaceutical Association (KPA) and Pharmaceutical Society of Kenya (PSK).

The discussions centered on various issues affecting the profession and the enforcement of discipline among professional members, including self-regulation mechanisms. The EDC committee is poised to conduct disciplinary hearings in the near future.

Pharmacy and Poisons Board Participates in the Government Performance and Delivery Roadshow



KEY ACHIEVEMENTS

1. Increased drugs and non pharmaceuticals availability at KEMSA from 28% in 2022 to 64% in 2023.
2. Increased access to safe blood and blood components for transfusion from 273,349 pints in 2022 to 412,531 in 2023, a 51% increase.
3. Increased number of vulnerable households covered by NHIF from 1.1m in 2022 to 1.3m in 2023, a 10% increase.
4. Increased number of NHIF paying members from 7m in 2022 to 7.6m in 2023.
5. Training, provision of gadgets and kits for the 100,000 Community Health Promoters.
6. Payment of stipends to the 100,000 CHPs at a rate of Ksh2,500 per month in the FY 23/24.
7. Trained 16,000 Health Care Workers in 2022, 23,000 in 2023 an increase of 43.5%



KEY COMMITMENTS

1. Increase availability of drugs and non pharmaceuticals at KEMSA from 64% to 75% in 2024 towards 100% by 2027
2. Increase access to safe blood by 20% in 2024 to 495,037 pints towards a target of 550,000 pints by 2027.
3. Increase the number of vulnerable households and indigenes under social health insurance from 1.3m to 2.9m households in 2024
4. Increase number of NHIF paying members to 8m in 2024 towards 10m in 2027
5. Digitize 7,000 facilities in 2024 and another 7,000 by 2025
6. Increase the number of community health promoters by 7% to 107,000 in 2024
7. Absorb trained and unemployed 3,300 doctors and 16,664 nurses both locally and internationally in 2024.

On January 26, 2024, Dr. F. M. Siyoi, Chief Executive Officer of the Pharmacy and Poisons Board, actively participated in Day 10 of the Government Performance and Delivery Roadshow at the Ministry

of Health held at KEMRI. Led by CS Hon Moses Kuria, Health CS Nakhumicha S. Wafula, PSs Mary Muthoni, and Harry Kimtai, the assessment aimed to

review the Ministry of Health's achievements and commitments over the past year in alignment with the government's Bottom-up Economic Transformation Agenda.

Pharmacy and Poisons Board CEO Engages with PMI Kenya Team



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi chairs a meeting with the PMI team.

On January 17, 2024, the Pharmacy and Poisons Board, led by Chief Executive Officer Dr. F. M. Siyoi, held a consultative meeting with the Presidents Malaria Initiative (PMI) Kenya team, led by Dr. Mildred Shieshia, to discuss areas of continued collaboration on quality assurance of antimalarial and other health products and technologies (HPTs) in Kenya. The team also discussed progress of PPB in achieving the World Health Organization’s Maturity Level 3 (ML3) status.

Pharmacy and Poisons Board CEO Hosts MSH Vice President Dr. Day Adetosoye



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi during a visit by the MSH Vice President Dr. Day Adetosoye.

On February 01, 2024, the Chief Executive Officer of the Pharmacy and Poisons Board (PPB), Dr. F. M. Siyoi, welcomed Dr. Day Adetosoye, Vice President of Management Sciences for Health

(MSH), along with the MSH-Kenya team consisting of Dr. Kusu and Dr. Mukoko.

Discussions focused on past and ongoing PPB-MSH regulatory system strengthening activities, highlighting innovations such as the PvERS tool, which has improved pharmacovigilance reports. The meeting also explored potential areas of collaboration for the future.



Ensuring quality, safe, efficacious and affordable health products and technologies in Kenya

Pharmacy and Poisons Board CEO Hosts U.S. Pharmacopeia Vice President and PQM+ Director for Enhanced Collaborative Initiatives



U. S. Pharmacopeia Vice President & PQM+ Director, J IkeNwokike visits the Pharmacy and Poisons Board Quality Control Laboratory alongside Chief Executive Officer, Dr. F. M. Siyoi.

On February 02, 2024, U.S. Pharmacopeia Vice President and PQM+ Director, J IkeNwokike, met with Pharmacy and Poisons Board (PPB) Chief Executive Officer Dr. F. M. Siyoi to discuss the collaborations

PQM+ has had with PPB over the years. The team explored further areas to support PPB in strengthening the quality assurance of health products and technologies in

the country, as well as bolstering local pharmaceutical production. Additionally, they reviewed PPB's progress towards achieving the World Health Organization Maturity Level 3 (ML3) status.

Pharmacy and Poisons Board Hosts Algerian Trade Mission



On February 29, 2024, the Pharmacy and Poisons Board (PPB) welcomed a delegation from the Algerian Trade Mission, who were in the

country to explore collaboration opportunities within the health sector. Talks during the meeting highlighted potential avenues for

Algerian health products to enter the Kenyan market, signaling promising prospects for bilateral cooperation.



Pharmacy and Poisons Board Chairman and CEO Host Biovax Institute Top Leadership



On March 19, 2024, the Chairman of the Pharmacy and Poisons Board (PPB), Dr. Charles Githinji, and Chief Executive Officer, Dr. F. M. Siyoi, hosted the top leadership of the Kenya Biovax Institute. The delegation included Chairman Mr. Mugo Kibati and Chief Executive Officer Dr. Michael Lusiola.

The discussion primarily centered on Biovax’s mandate to manufacture, package, and commercialize specialized health products and technologies, such as human vaccines, therapeutics, and other biomedical products. Additionally, the meeting included a review of Kenya’s progress towards achieving Maturity Level 3.

Pharmacy and Poisons Board Chairman, Dr. Charles Githinji, Chief Executive Officer, Dr. F. M. Siyoi and BIOVAX top leadership, Chairman Mr. Mugo Kibati & CEO Dr. Michael Lusiola pose for a photo.

Pharmacy and Poisons Board Shares Clinical Trials Insights with Walter Reed Army Institute of Research

On March 25, 2024, a delegation from the Walter Reed Army Institute of Research (WRAIR) Institutional Review Board (IRB) visited the Pharmacy and Poisons Board (PPB) to familiarize themselves with the processes of PPB’s Expert Committee on Clinical Trials (ECCT). They were warmly received by PPB’s Chief Executive Officer, Dr. F. M. Siyoi, and the Chairman of the ECCT, Prof. Gilbert Kokwaro.

During the visit, Dr. Siyoi highlighted the significant advancements made by PPB in the field of clinical trials, including the development of a draft framework for parallel submission of applications. This step aims to improve the review timelines for clinical trials in the country.

The visiting team expressed appreciation for the strides taken by PPB in overseeing clinical trials,



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi during the meeting.



particularly in the automation of its processes, which facilitates a seamless approach to submissions.



A group photo after the meeting.

Pharmacy and Poisons Board Conducts Workshop to Enhance Quality of HPTs



Participants pose for a photo after the workshop.

Development Plans (IDPs) related to market surveillance & control and regulatory system (RS) functions. PPB expresses gratitude for the continued support offered by USAIDKenya and PMlgov towards strengthening medicines regulatory systems in Kenya.

On March 27, 2024, the Pharmacy and Poisons Board (PPB), with support from USAID Kenya and PMlgov through USPGlobalHealth, conducted a five-day workshop aimed at improving quality assurance systems for antimalarials and other health products and technologies (HPTs) in Kenya.

PPB is working towards achieving Maturity Level 3 status/ categorization by the World Health Organization (WHO) through the Global Benchmarking process (GBT).

The team addressed Institutional



Workshop Participants during group sessions.

Pharmacy and Poisons Board Engages KAPI and MEDAK Stakeholders



Pharmacy and Poisons Board Chief Executive Officer, Dr. F. M. Siyoi and Dr. James Mukoro during the meeting.



Dr. Paulyne Wairumu, Head Medical Devices shares her insights during the meeting.



On March 27, 2024, the Pharmacy and Poisons Board (PPB) convened a meeting with representatives from the Kenya Association of Pharmaceutical Industry (KAPI) and the Medical Technology Industry Association of Kenya (MEDAK) to address pivotal challenges

and progressions within the pharmaceutical and medical device sectors.

During the meeting, both parties committed to fostering collaboration to fortify regulatory frameworks, ensuring access to top-tier, secure, and efficient health

products and technologies (HPTs). Leading the PPB delegation was Chief Executive Officer Dr. F.M. Siyoi, while Dr. James Mukoro represented KAPI and Mr. Steve Kipkoti represented MEDAK, respectively.

PHARMACY AND POISONS BOARD

NOTICE CLOSED

Due to lack / Suspension of authorisation permit, this premises is hereby closed

NO NAME CHEMIST ESTABLISHMENT

Premise Name: **ESTABLISHMENT**

Premise Address / Location: **DRA**

This premise was found to have violations which constitute an immediate danger to the public health and safety; as a result the permit to operate as drug outlet has been suspended until a written reinstatement has been issued.

Category of violation(s) resulting to closure:

- Unlawfully carrying on the business of a pharmacist while not registered as a pharmacist by the Pharmacy and Poisons Board contrary to section 19(2) of the Pharmacy and Poisons Act, Cap 244 laws of Kenya
- Carrying on the business of a pharmacy in premises not registered by the Pharmacy and Poisons Board contrary to section 24(6) of the Pharmacy and Poisons Act, Cap 244 laws of Kenya

"We are dedicated to curbing unlawful practices in the pharmaceutical sector to ensure the well-being of all citizens." - Kaluai Julius, Head of Enforcement and Surveillance



REPUBLIC OF KENYA
**MINISTRY OF HEALTH
PHARMACY AND POISONS BOARD**

LIST OF REGISTERED AND LICENSED PHARMACEUTICAL OUTLETS IN KENYA

The Pharmacy and Poisons Board (PPB) is the Drug Regulatory Authority established under the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya. The PPB has the sole responsibility to protect the health of the public by regulating the profession of pharmacy and ensuring the quality, safety, and efficacy of medical products and health technologies.

In execution of its mandate, the PPB conducts the registration and licensing of pharmaceutical outlets, including pharmaceutical manufacturers, wholesalers, distributors, pharmacies (including those in hospitals and clinics), and other retail outlets in line with the provisions of the Act.

In this regard, the PPB has taken note of an unverified list of pharmaceutical outlets circulating on social media, and wishes to clarify as follows:

1. The registration of outlets is a continuous process. As such, the list of licensed pharmaceutical outlets is updated on a real-time basis to reflect any decision on approval, suspension, revocation or closure.
2. Authorized outlets are issued licenses bearing a QR Code. The QR Code can be scanned using any smart phone to verify the authenticity of the license.
3. The list of licensed pharmaceutical outlets as at **11th March 2024 has been provided** and sorted by county, constituency and ward. Further verification can be made by **searching the website or scanning the QR Code** on the license displayed at the outlets.
4. The list of licensed pharmaceutical outlets is publicly available on the PPB website accessible via
<https://practice.pharmacyboardkenya.org/LicenseStatus?register=facilities>

In case of any queries do not hesitate to contact us via email: practice@pharmacyboardkenya.org or practice@ppb.go.ke or telephone 0709 770 100

The PPB remains committed to protection of the health of the public.


Dr. F. M. Siyoi
CHIEF EXECUTIVE OFFICER